Inhibikase Therapeutics, Inc. IKT
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a respiratory drug developer. Its lead program, IKT-001 (imatinib prodrug), IMPROVE-PAH, is in Phase 3 for Pulmonary arterial hypertension. Its next catalyst on record is IKT-001: Topline data readout in Part B of IMPROVE-PAH Phase 3 (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: IKT-001 — Topline data readout in Part B of IMPROVE-PAH Phase 3 (date not stated). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| IKT-001 | Pulmonary arterial hypertension (single pivotal Phase 3 IMPROVE-PAH) | small molecule | Phase 3 |
Recent results and decisions
- May 12, 2026n/a EMA confirmed the company may initiate the Phase 3 IMPROVE-PAH study in 12 EU countries, bringing total country approvals to 16.
Inhibikase received confirmation from the European Medicines Agency that the Company is permitted to initiate our Phase 3 study in PAH, named IMPROVE-PAH
Filing - Apr 7, 2026started First patient enrolled in the global pivotal Phase 3 IMPROVE-PAH study of IKT-001 in PAH.
announced today that the first patient has been enrolled in the Company’s pivotal Phase 3 study IMPROVE-PAH
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 respiratory companies
- United Therapeutics Corporation UTHR
- Insmed Incorporated INSM
- Liquidia Corp LQDA
- Trevi Therapeutics, Inc. TRVI
- Generate Biomedicines, Inc. GENB
- Savara Inc SVRA
- Apnimed, Inc. APMD
- Gossamer Bio, Inc. GOSS
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.